Successful Endovascular Repair of a Symptomatic Descending Thoracic Aortic Aneurysm in a 90-Year-Old Gentleman: A Case Report
Abstract
Thoracic aortic aneurysms (TAAs) carry high mortality without intervention, and thoracic endovascular aortic repair (TEVAR) has become a preferred minimally invasive option for high-risk patients. We report a 90-year-old male with prostate cancer and type 2 diabetes, who presented with hemoptysis and left-sided chest pain, initially attributed to lobar pneumonia but later diagnosed as a 40 mm saccular descending TAA compressing the left lung on CT angiography. The patient underwent successful TEVAR with complete symptom resolution and was discharged within five days, demonstrating TEVAR's efficacy in fragile elderly patients. This case highlights TEVAR's advantages over open repair, including reduced morbidity and faster recovery, while underscoring the need for further research on long-term outcomes and anatomical limitations in complex cases to refine patient selection and expand applications.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.